[1]Patent:WO2006/66806,2006,A1,.Locationinpatent:Page/Pagecolumn16
[2]Patent:WO2013/167991,2013,A1,.Locationinpatent:Paragraph00103;00104
[3]Patent:US2015/141468,2015,A1,.Locationinpatent:Paragraph0110;0119;0120
[1]Patent:WO2005/77902,2005,A2,.Locationinpatent:Page/Pagecolumn40-42
[1]PharmaceuticalChemistryJournal,1980,vol.14,#6,p.407-409
[2]Khimiko-FarmatsevticheskiiZhurnal,1980,vol.14,#6,p.79-81
[1]PharmaceuticalChemistryJournal,1980,vol.14,#6,p.407-409
[2]Khimiko-FarmatsevticheskiiZhurnal,1980,vol.14,#6,p.79-81
[1]JournalofOrganicChemistry,1957,vol.22,p.825
[1]PharmaceuticalChemistryJournal,1980,vol.14,p.407-409 Khimiko-FarmatsevticheskiiZhurnal,1980,vol.14,p.79-81
[1]JournaloftheAmericanChemicalSociety,1986,vol.108,p.1969-1979
[1]Tetrahedron,1988,vol.44,p.7283-7292
[1]JournaloftheAmericanChemicalSociety,2003,vol.125,p.12110-12111
Title: Pyridorin in type 2 diabetic nephropathy.
Journal: Journal of the American Society of Nephrology : JASN 20120101
Title: Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy.
Journal: Journal of the American Society of Nephrology : JASN 20120101
Title: Stitt A, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32.